Moleculin Biotech, Inc.MBRXEarnings & Financial Report
Moleculin Biotech, Inc. is a clinical-stage biotechnology company focused on developing innovative oncology therapies for difficult-to-treat cancers. Its core pipeline includes candidates targeting brain tumors, pancreatic cancer and other rare malignancies, with primary operations in the United States addressing high unmet patient needs.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-6.2M
Net Profit
$-6.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-2.37
Moleculin Biotech, Inc. Q2 FY2024 Financial Summary
Moleculin Biotech, Inc. reported revenue of $0 for Q2 FY2024, with a net profit of $-6.0M (down 0.7% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-6.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2024 |
Moleculin Biotech, Inc. Annual Revenue by Year
Moleculin Biotech, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2025 | $0 |
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
Moleculin Biotech, Inc. Quarterly Revenue & Net Profit History
Moleculin Biotech, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $15.6M | N/A |
| Q3 FY2025 | $0 | — | $-25.4M | N/A |
| Q2 FY2025 | $0 | — | $-17.8M | N/A |
| Q1 FY2025 | $0 | — | $-5.9M | N/A |
| Q4 FY2024 | $0 | — | $-6.6M | N/A |
| Q3 FY2024 | $0 | — | $-7.0M | N/A |
| Q2 FY2024 | $0 | — | $-6.0M | N/A |
| Q1 FY2024 | $0 | — | $-6.4M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $30.8M | $25.6M | $23.4M | $16.9M | $21.0M | $21.6M | $20.4M | $22.1M |
| Liabilities | $9.3M | $7.9M | $15.9M | $5.7M | $7.2M | $25.2M | $47.3M | $7.1M |
| Equity | $25.0M | $19.4M | $17.4M | $11.2M | $13.8M | $-3.6M | $-26.9M | $15.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.7M | $-5.9M | $-6.1M | $-5.1M | $-4.6M | $-5.6M | $-7.2M | $-5.4M |